MP-2026-VTX-G · Vantrexa · Oncology / Non-small cell lung cancer
PRD planning workflow. The current state is highlighted.
First-line metastatic NSCLC launch in five priority markets. Differentiation rests on durable response in PD-L1 high patients and a manageable immune-related adverse event profile versus checkpoint monotherapy.
Long-term overall survival beyond 36 months
No project yet
Sequencing after progression on vantrelimab
Outcomes in brain-metastasis subgroup
SO-VTX-01
Guideline inclusion and KOL advocacy are the primary drivers of early appropriate use.
Linked initiatives (2)
SO-VTX-02
Sequencing uncertainty is the most frequent insight theme from field interactions (34 insights in H1).
Linked initiatives (2)
SO-VTX-03
Testing turnaround is the rate-limiting step for appropriate patient identification.
Linked initiatives (1)
SO-VTX-04
Launch readiness depends on consistent, approved scientific content.
Linked initiatives (1)
Planned versus delivered, and activity versus outcome for this product.
Initiatives completed
0 / 6
1 at risk or blocked
Milestones
12 / 23 done
9 on time · 3 late · 1 overdue · 10 upcoming
Budget consumed
71%
$5.9M of $8.4M · initiatives $1.5M of $3.3M
Activity → outcome
114 → 33 → 2
Engagements → insights → actions for this product
Activity counts (engagements) are not outcomes. Insights and actions are shown alongside so that activity is read against what it produced. Budget figures for the plan come from Finance; initiative spend is entered by initiative owners.
Newest first. Each version records who changed the plan and what changed.
20 Jan 2026 · v3
Approved. Sequencing evidence gap elevated to strategic objective.
By Dr. Helen Okafor · current version
16 Dec 2025 · v2
Added Japan launch objective; revised budget after Finance review.
By Dr. Priya Raman
04 Nov 2025 · v1
Initial draft for FY2026 planning cycle.
By Dr. Priya Raman
| Risk | Description | Initiative | P × I | Status | Owner |
|---|---|---|---|---|---|
| RSK-0001 | SEQUENCE-RW data-licensing negotiation fails, leaving the sequencing evidence gap open at EU launch. | INI-0102 | 4 × 4 = 16 | Escalated | NPDr. Nikolai Petrov |
| RSK-0004 | Competitor TIGIT class scepticism reduces KOL willingness to adopt chemotherapy-free regimen. | INI-0101 | 3 × 3 = 9 | Mitigating | PRDr. Priya Raman |
| RSK-0005 | Compliance review backlog delays plain-language summary and PLS-related launch content. | INI-0105 | 4 × 2 = 8 | Mitigating | OBOliver Brandt |
| RSK-0012 | Over-contact of Tier 1 US oncologists (some engaged 6+ times in H1) risks stakeholder fatigue. | INI-0101 | 2 × 2 = 4 | Closed | JWJames Whitfield |
| Dependency | Dependent | Depends on | Type | Due | Status | Impact if delayed |
|---|---|---|---|---|---|---|
| DEP-0001 | SEQUENCE-RW RWE cohort | Data-licensing clause decision (Decision) | Internal | 30 Sept 2026 | Blocked | First data cut slips past EU launch |
| DEP-0007 | MI response library | Compliance review capacity (Review) | Cross-functional | 30 Sept 2026 | At risk | 4 infusion-reaction responses not approved pre-launch |
| Initiative | Type | Objective | Owner | Priority | Status | Progress | End |
|---|---|---|---|---|---|---|---|
| Tier 1 thoracic oncology KOL engagement programme | Field medical campaign | SO-VTX-01 | JWJames Whitfield | Critical | In progress | 66% | 15 Dec 2026 |
| Post-progression sequencing RWE cohort (SEQUENCE-RW) | RWE project | SO-VTX-02 | NPDr. Nikolai Petrov | High | At risk | 30% | 30 Jun 2027 |
| Sequencing expert consensus manuscript | Publication project | SO-VTX-02 | DCDavid Chen | High | In progress | 55% | 31 Dec 2026 |
| PD-L1 pathology education programme | Medical education program | SO-VTX-03 | SLDr. Sophie Laurent | High | In progress | 78% | 30 Nov 2026 |
| Vantrexa scientific communication platform and MI response library | Launch-readiness workstream | SO-VTX-04 | DCDavid Chen | Critical | In progress | 90% | 30 Sept 2026 |
| ESMO 2026 congress plan | Congress activity | SO-VTX-01 | DCDavid Chen | High | In progress | 60% | 31 Oct 2026 |
| Timestamp | Action | User | Field | Change | Reason | Source |
|---|---|---|---|---|---|---|
| 13 Sept 2026, 09:45 UTC | Export | OBOliver Brandt | — | Evidence package (PDF+CSV), 214 events | Q3 internal audit | UI · AUD-001788 |
| 20 Jan 2026, 14:02 UTC | Sign | HODr. Helen Okafor | signature | Meaning: Approval · Re-authenticated | — | UI · AUD-000902 |
| 20 Jan 2026, 14:02 UTC | Approve | HODr. Helen Okafor | status | Medical approval → Active | Approved at Q1 leadership review | UI · AUD-000901 |